Periprocedural Myocardial Injury: Pathophysiology, Prognosis, and Prevention.

The definition and clinical implications of myocardial infarction occurring in the setting of percutaneous coronary intervention have been the subject of unresolved controversy. The definitions of periprocedural myocardial infarction (PMI) are many and have evolved over recent years. Additionally, the recent advancement of different imaging modalities has provided useful information on a patients' pre-procedural risk of myocardial infarction. Nonetheless, questions on the benefit of different approaches to prevent PMI and their practical implementation remain open. This review aims to address these questions and to provide a current and contemporary perspective.
Competing Interests: Declaration of competing interest Ron Waksman, MD, received honoraria from Abbott Vascular, Amgen, Boston Scientific, Chiesi, Medtronic and Philips Volcano, and consulting fees from Biosensors, Biotronik, Corindus, Lifetech Medical, and Pi-Cardia LTD. He is on the advisory boards of Abbott Vascular, Amgen, Boston Scientific, Medtronic, Philips Volcano, and Pi-Cardia LTD, is a consultant for Abbott Vascular, Amgen, Biosensors, Biotronik, Boston Scientific, Corindus, Lifetech Medical, Medtronic, Philips Volcano, and Pi-Cardia LTD, received grant support from Abbott Vascular, Biosensors, Biotronik, Boston Scientific, Chiesi and Edwards Lifesciences, and is an investor in MedAlliance. All other authors have no conflicts of interest to disclose.
(Copyright © 2020 Elsevier Inc. All rights reserved.)